Compare Organon & Co. Common Stock (OGN) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ProShares Ultra Semiconductors — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ProShares Ultra Semiconductors trades at $80.63 (market cap $2.80B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and ProShares Ultra Semiconductors for 30 Days on average.
| OGN | USD | |
|---|---|---|
Market Cap | $3.62B | $2.80B |
Volume | 2,892,999 | 467,963 |
Sector | Health | Leveraged / Inverse |
52-Week High | $13.81 | $113.53 |
52-Week Low | $5.70 | $43.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
USD stock trades at $91.26 with a modest 0.26% daily gain, showing neutral momentum amid bearish technical signals. The company declared a $0.13 dividend for H2-2026, payable September 29, 2026. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support sits at $90 and resistance at $93.
Fundamental data remains limited with key ratios unavailable, requiring deeper financial review. The stock faces headwinds from bearish technical trends but maintains dividend distribution. Investment appeal hinges on upcoming financial disclosures and market sentiment shifts amid current neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
